Operations

Our research and development focus is on specific protein molecules rather than therapy areas, where we prioritize pharmaceuticals against infectious diseases caused by virus.

Medivir’s core competence consists of its knowledge of the enzymes polymerase and protease. We have invested in competence, accumulated experience, built unique compound libraries and developed competitive CDs (candidate drugs) which make us an attractive collaboration partner for the large pharmaceutical companies.

Our pharmaceutical research is based on our competence in preventing and inhibiting the activity of polymerases and proteases with our focus on infectious diseases. The main part of our projects are in these segments. We have a long history of producing experimental drugs against diseases including HIV, herpes and hepatitis. Right now, Medivir and our collaboration partners have very high expectations of our hepatitis C project, TMC435.